Carcinoid Tumors Clinical Trial
Official title:
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
This research study is evaluating the drug Ramucirumab as a possible treatment for Advanced, Progressive Carcinoid Tumors.
This research study is a Phase II clinical trial. The purpose of this study is to test the safety and effectiveness of ramucirumab in advanced, progressive carcinoid tumors. Cancer cells can make growth factors that cause the abnormal growth of new blood vessels. Ramucirumab is an investigational drug which works by blocking a receptor for a vascular growth factor, thereby preventing new blood vessels from forming. This may stop the cancer from growing or spreading and the tumor cells may die. The FDA (the U.S. Food and Drug Administration) has not approved Ramucirumab for treatment of Carcinoid Tumors. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02441062 -
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT00580320 -
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
|
Phase 1 | |
Completed |
NCT02575300 -
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Active, not recruiting |
NCT02441088 -
Theranostics: 68GaDOTATOC and 90YDOTATOC
|
Phase 2 | |
Terminated |
NCT00227136 -
Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion
|
Phase 3 | |
Terminated |
NCT00947167 -
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
|
Phase 2 | |
Terminated |
NCT02177773 -
GA-68 DOTA-TOC of Somatostatin Positive Malignancies
|
Phase 1/Phase 2 | |
Terminated |
NCT02859064 -
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
|
Phase 2 | |
Active, not recruiting |
NCT01731925 -
A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
|
Phase 2 | |
Completed |
NCT00088595 -
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
|
Phase 2 | |
Completed |
NCT01619865 -
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01253161 -
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
|
Phase 2 | |
Terminated |
NCT02359500 -
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
|
Phase 1 | |
No longer available |
NCT01980732 -
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
|
N/A | |
Not yet recruiting |
NCT01373736 -
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
|
Phase 3 |